Hypereosinophilic syndrome (HES) can cause eosinophilic infiltration in multiple organ systems resulting in organ damage. Among all, cardiac involvement is the major cause of morbidity and mortality. Early diagnosis and prompt treatment are important to improve the prognosis. We reported a 45-year-old woman with a history of eosinophilia presented with chest pain in our emergency department. Laboratory tests revealed marked eosinophilia and elevated cardiac markers. A neurological event, presenting as right-side limb weakness, supervened later. The diagnosis of HES was established, and prompt treatment with corticosteroids, hydroxyurea, and imatinib resolved the eosinophilia; further cardiac and neurological injury was thus prevented. This case reminds us to consider and, if applicable, to provide the appropriate management for HES in the context of making a differential diagnosis in clinical situations involving organ damage. (Hong Kong j.emerg.med. 2013;20:60-62) 嗜酸性細胞增多綜合徵(HES)可引起嗜酸性粒細胞浸潤，導致多個器官系統的損害。其中，心臟受 累是致病和死亡的重要原因。早期診斷和及時治療可以改善預後。我們報告一例嗜酸性粒細胞增多的45 歲女病人，因胸痛到診我們急診科。化驗結果顯示，嗜酸性粒細胞與心肌標誌物升高。後來並發右側肢 體無力的神經系統症狀。HES的診斷成立，及時使用皮質類固醇，羥基脲，和伊馬替尼治療，解決了嗜 酸性粒細胞增多，從而防止進一步的心臟和神經系統損傷。這個案例提醒我們，在器官損害的臨床背景 下作出鑑別診斷，可以考慮 HES 及(如適用)提供合適 HES 的治療。
Introduction
Hypereosinophilic syndrome (HES), defined as persistent marked eosinophilia (>1 500 eosinophils/ L) of unspecified origin for at least 6 months with evidence of eosinophil-mediated end-organ damage, is a rare disorder. 1, 2 HES frequently involves the cardiovascular system as a major complication and results in morbidity or mortality. The cardiovascular system is often involved as a major complication (58% frequency), resulting in morbidity and mortality. Other organs, including the respiratory, gastrointestinal, neurological, cutaneous, and ocular systems can also be affected. [2] [3] [4] [5] We report a case of HES with cardiac and neurological involvement that initially presented in the emergency department (ED) with acute chest pain.
Case report
A 45-year-old woman presented in our ED with acute chest pain of several hours. The patient had no previous medical history, except eosinophilia which was revealed nearly one year ago at an outpatient department. The chest pain was precordial, oppressing and tight in character, and with no radiation. The patient had experienced intermittent chest pain for 1 week, but chest pain became persistent, prompting an ED visit. She denied shortness of breath, fever, cough, recent chest trauma, or gastrointestinal upset. On arrival at our ED, the patient appeared acutely ill but was afebrile (37.3°C). Pertinent vital signs included a respiratory rate of 20/min, heart rate of 111/min, and blood pressure of 143/110 mmHg. Physical examination r e v e a l e d c l e a r b r e a t h s o u n d s a n d r e g u l a r heartbeat without audible murmur. Twelve-lead electrocardiography showed sinus tachycardia without ST-segment change. Chest films revealed no specific findings. Haemography showed leukocytosis with eosinophil predominance (white blood cell count, 20 000/L; eosinophils, 8 400/L). Blood chemistry was within normal limits, except for an elevated cardiac troponin-I level of 3.50 ng/mL (normal range: <0.05 ng/mL). Transthoracic echocardiography revealed adequate left ventricular function without asynergy or thrombus formation. Other possible aetiologies of eosinophilia, such as allergic reaction, medication use, or parasitic infection were excluded by history. We suspected this patient had HES with cardiac involvement.
The patient was admitted to the intensive care unit and intravenous methylprednisolone (2 mg/kg/day) was started. On the third day of hospitalisation, the patient developed sudden-onset right-limb weakness. Brain magnetic resonance imaging revealed multiple small infarcts in the periventricular and subcortical white matter in the absence of vascular stenosis. We s u s p ec t ed H E S w it h c en t r a l n er v o u s s y s t em involvement, and after discussion with a haematologist, we added imatinib (400 mg/day), hydroxyurea (1 g every 8 h), and subcutaneous enoxaparin (1 mg/kg every 12 h) to this patient.
Subsequent haemogram showed the resolution of eosinophilia (1 053/mL) in 1 week. Tests for the FIP1L1-PDGFR  gene fusion transcripts and antineutrophilic cytoplasmic antibodies were both negative. Bone marrow biopsy revealed prominent eosinophils without blast cells. The patient reported no additional chest pain and was transferred to the floor 1 week later. Steroid therapy was then tapered, and imatinib and hydroxyurea were discontinued after 2 weeks. The patient was discharged with improved right-side hemiparesis after 1 month.
Discussion
HES is a rare disorder that can result in life-threatening clinical manifestations. Modern definitions of HES have been modified and the 6-month duration of abnormalities no longer becomes mandatory if other criteria are met. 6 HES involves various organs, and the extent of organ involvement varied as was reported in previous studies. 1, 7 Cardiac involvement, characterised by eosinophilic infiltration of the myocardium, is a severe complication, which is subsequently associated with myocardial necrosis (acute necrotic change), intramural thrombus formation (thrombotic stage) and myo c a rd ia l f ib ro s is ( f ib ro t i c s t a g e) . 1, 3 Th es e cardiovascular changes are major causes of morbidity and mor tality in HES. 2, 3, 8 Another impor tant complication is neurological involvement, which is probably caused by eosinophil-mediated damage to endothelial cells. 3, 9, 10 The patient reported herein, although suffering from myocardial and brain injuries, did not eventually develop sequelae except mild right-sided hemiparesis from these injuries due to the prompt diagnosis and aggressive treatment. Although a myocardial biopsy to confirm the presence of eosinophilic infiltration was not performed, we still believed that the myocardial injury in this patient was a manifestation of HES. Also the patient became free of chest discomfort after the treatment we prescribed. Aggressive treatment can ameliorate the development of complications. To achieve this, emergency physicians need to have an understanding of and familiarity with this syndrome.
Traditionally, corticosteroids is the treatment for HES, albeit without a standard dosage. Corticosteroids leads to complete or partial responses in 1 month in 85% of patients. 7 We started intravenous methylprednisolone at a dose of 2 mg/kg/day. However, neurological involvement supervened, and imatinib, hydroxyurea, and low-molecular-weight heparin were subsequently added. Imatinib, which inhibits tyrosine kinase activity, has been shown to have a positive contribution to the treatment of HES, especially in those with the FIP1L1-PDGFR  mutation. 7, 11 Pending the results of FIP1L1-PDGFR  mutation analysis, empiric treatment with imatinib in urgent scenarios, as in this case, may provide benefits in addition to steroids. Hydroxyurea was the preferred second-line therapy and was used alone or in combination with corticosteroids. 7 Our patient responded to the treatment with resolution of eosinophilia and absence of new episodes of chest pain or neurological deficits.
HES is a rare disease that may cause possible fatal complications. Early diagnosis and prompt treatment are important. Emergency physicians should have more understanding and vigilance to this syndrome, as aggressive treatment can ameliorate the development of complications.
